Skip to main content
PathMaker Neurosystems logo

PathMaker Neurosystems

Boston, MassachusettsFounded 2015

  • Neuromodulation
  • ALS

PathMaker Neurosystems is a clinical-stage medical device company developing non-invasive neuromodulation treatments for ALS and other neurological disorders. Its Multi-Site DCS approach is designed to stimulate neural pathways at multiple points, with the goal of restoring function and slowing ALS disease progression.

Trial
1
Raised
$8.4M
Investors
5
Founded
2015
Employees
1–10

reccy insights

Recent highlights

PathMaker’s recent milestones center on advancing its investigational MyoRegulator® program for ALS. On January 12, 2026, the company announced completion of an early-feasibility study evaluating the device as a non-invasive ALS treatment; the announcement establishes a study milestone but does not report clinical results. On December 17, 2025, the FDA granted MyoRegulator Breakthrough Device Designation for use in ALS, with the intended goal of slowing progression of functional symptoms. In July 2025, PathMaker announced publication of a study reporting increased survival in an ALS mouse model after non-invasive neuromodulation, a preclinical finding rather than evidence of benefit in people. Earlier, in March 2025, it reported issuance of three patents related to its ALS neuromodulation technology. Its listed funding total is $8,431,000 across seven rounds, including a $2.16 million 2024 grant and a $5 million 2018 grant.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes PathMaker Neurosystems distinct

  1. 01Focuses on non-invasive neuromodulation for ALS and other serious neurological disorders.
  2. 02Its Multi-Site DCS approach stimulates multiple points along neural pathways, distinguishing it from single-site stimulation approaches.
  3. 03DoubleStim® technology is used in the MyoRegulator® device in ALS clinical trials.
  4. 04The company states that it holds exclusive worldwide rights to foundational intellectual property covering multi-site neuromodulation.
  5. 05Its stated mission is to help make ALS a livable disease by developing treatments intended to restore damaged neural pathways.

Technology & products3

  • MyoRegulator®

    An investigational, non-invasive neuromodulation device intended to reduce muscle spasticity associated with stroke and other neurological disorders through synchronized spinal and peripheral direct-current stimulation.

  • MyoRegulator® ALS

    An investigational non-invasive neuromodulation program for ALS designed to suppress motor-neuron hyperexcitability and potentially address disease-related neural dysfunction.

  • Multi-Site DCS Technology

    A proprietary neuromodulation technology that applies synchronized direct-current stimulation at multiple neural sites to modulate abnormal neural activity without surgery.

Clinical trials1

Recent updates5

  • Feb 5, 2026Award

    PathMaker Neurosystems Board Director, John Donoghue, Ph.D., Awarded 2026 Queen Elizabeth Prize for Engineering

    pmneuro.com
  • Dec 17, 2025Product launch

    PathMaker Neurosystems received FDA Breakthrough Device Designation for its investigational MyoRegulator neuromodulation device, a non-invasive treatment aimed at slowing progression of functional symptoms in ALS patients; the device is being evaluated in the CALM clinical trial.

    globenewswire.com
  • Dec 17, 2025Award

    FDA Breakthrough Device Designation for MyoRegulator in ALS

In the Cortex

Funding

$8.4M disclosed
5 investors

Similar companies

About PathMaker Neurosystems

Products
MyoRegulator®, MyoRegulator® ALS, Multi-Site DCS Technology
Leadership
Nader Yaghoubi, Co-Founder and Chief Executive Officer
Focus areas
Neurotechnology, medical devices, biotechnology, digital health, therapeutics, clinical research, ALS, neuromodulation
Headquarters
Boston, Massachusetts
Founded
2015
Employees
1–10
Patents granted
2
Trademarks
7